Cart
sales@molnova.com
Sabatolimab
CAS No. 2252262-24-9
Sabatolimab( —— )
Catalog No. M36672 CAS No. 2252262-24-9
Sabatolimab (MBG453), a humanized IgG4 (S228P) antibody targeting TIM-3, is a potent inhibitory receptor that regulates adaptive and innate immune responses.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 511 | In Stock |
|
| 10MG | 867 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSabatolimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSabatolimab (MBG453), a humanized IgG4 (S228P) antibody targeting TIM-3, is a potent inhibitory receptor that regulates adaptive and innate immune responses.
-
DescriptionSabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2252262-24-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood?(2020) 136 (Supplement 1): 1–2.
molnova catalog
related products
-
MD2-IN-1
MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD of 189 ?μM for the recombinant human MD2 (rhMD2).
-
Cephalonium
Cefalonium (INN) is a first-generation cephalosporin antibiotic.
-
β-Aminoarteether
β-Aminoarteether (SM934 free base), an orally active derivative of Artemisinin, serves a pivotal role in the research of inflammation and autoimmune disorders, including those related to lupus diseases.
